Notably, a stepwise transition may occur in NSCLC upon TKI treatment, tumor cells first reversibly enter a slow-cycling state, then regain proliferation and ultimately become drug-resistant through further epigenetic changes or via genetic modifications (such as EGFR-T790M) [6, 15]. The gene discussed is EGFR; the disease is neoplasm.